On the other hand, there is significant improvement in the sum rate once UEs resort to intelligent detection by employing the low-complexity interference-aware receivers.
There is a slight improvement in the sum rate at medium SNR when the restriction of low resolution (LTE quantized precoders) is relaxed, i.e., eNodeB employs MF EGT precoders; however, there is a significant improvement in the sum rate when the restriction of EGT is eliminated, i.e the eNodeB employs MF precoders.
With this, at every M inter frames, user k in cell i finds cell (i_{k}^{ast }) that achieves the largest improvement in the sum of log throughputs of the users in ({mathcal {U}}_{i}) and ({mathcal {U}}_{i_{k}^{ast }}) if user k is offloaded to cell (i_{k}^{ast }).
Intra-cell user association: At every M intra frames, small cell i chooses user k ⋆ in ({mathcal {V}}_{i}) (({mathcal {W}}_{i})) that achieves the largest improvement in the sum of log throughputs of all users in ({mathcal {U}}_{i}) if it moves to ({mathcal {W}}_{i}) (({mathcal {V}}_{i})).
A subcarrier will be moved to a different allocation set N k if this leads to an improvement in the sum rate R. To keep computational effort low, the available power will be distributed uniformly among subcarriers for the computation of rates r n,k.
Patients receiving bibrocathol 2%% showed greater improvement in the sum score than the placebo patients (p < 0.0001, Cohen's effect size d = 0.73).
A complete response was defined as complete resolution of disease in all three body compartments, and a partial response was defined as ≥50% improvement in the sum of the three assessments with ≥30% improvement in the skin, no worsening lymph nodes or Sézary cells, and no new tumors.
The reduced length sequence shows excellent performance and results in an 47% improvement in the sum-squared error (SSE) value of the third-order sub-diagonal kernel.
A phase II proof-of-concept study completed in Japan demonstrated a significant improvement in the summed sensory NCV with ranirestat compared with placebo after 26 weeks of treatment although the placebo group in this study also improved (T.-H., personal communication).
Significant improvement in the summed motor (peroneal, tibial, and median) NCV was observed with 20 and 40 mg/day ranirestat treatment at week 12 (P ≤ 0.05) and at weeks 24 and 36 and in peroneal motor NCV at weeks 36 and 52 (P ≤ 0.05) for the 20 mg/day ranirestat group.
